Incyte Stock Dips Despite Dermatitis Drug Buzz

INCY shares are just coming off a 10-month high

Digital Content Manager
Feb 4, 2019 at 10:32 AM
facebook X logo linkedin


The shares of Incyte Corporation (NADSAQ:INCY) were pointed higher in pre-market trading, after the company's experimental atopic dermatitis treatment met the main goal in two late-stage studies. The drug, which is being marketed as Olumiant, was jointly developed with pharma giant Eli Lilly (LLY). However, INCY shares have since turned lower, down 1.6% at $81.57.

The stock is coming off a 10-month high, and recently popped above the $80 area for the first time since an early April bear gap. In fact, the shares gained 26.7% in January -- their biggest one-month gain since 2014. Their 14-day Relative Strength Index (RSI) now sits at 69 -- in the cusp of overbought territory, suggesting a short-term breather may have been in the cards for INCY.

The majority of analysts are bullish on INCY stock. Eleven give it a "strong buy" rating and one considers it a "buy," compared to six doling out tepid "holds" and not a single "sell" to be found. On the other hand, the consensus 12-month price target of $85.63 falls right in line with current levels. Should the shares extend their 2019 rally -- or should Incyte report stronger-than-expected earnings next week -- there's room for price-target hikes. 

Options traders have been generally optimistic on the equity, with data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) showing INCY's 10-day call/put volume ratio of 4.44 sits higher than 76% of all other readings from the past year. This indicates a healthier-than-usual appetite for bullish bets over bearish of late. However, the stock's Schaeffer's Volatility Scorecard (SVS) sits at a low 8 out of a possible 100, indicating INCY has fallen short of options traders' volatility expectations in the past year.

 

Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls

 
 
 


 
 

Rainmaker Ads CGI